NICE rejects expanded treatment indication for Roche’s Esbriet
September 19, 2016Sales and Marketing Esbriet, NICE, Roche, rejection
NICE has published a final appraisal rejecting the expanded use of Roche’s Esbriet (pirfenidone) for the treatment of early idiopathic …
EU recommendation for Lilly’s soft tissue cancer drug
September 19, 2016Sales and Marketing CHMP, EMA, Eli Lilly, Lartruvo, soft tissue sarcoma
The Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Lartruvo (olaratumab) for treatment of adults with …
J&J in $4.33bn eye surgery unit acquisition
September 19, 2016Manufacturing and Production, Sales and Marketing Abbott, Johnson & Johnson, acquisition
Johnson & Johnson has agreed to buy Abbott Laboratories’ eye surgery equipment unit in an all-cash deal for £4.33 billion …
“First of its kind” manufacturing campus to bring 500 jobs to Ireland
September 19, 2016Manufacturing and Production, Sales and Marketing GE Healthcare, Ireland, manufacturing
Biopharma firm GE Healthcare has made a major investment to create a ‘BioPark’ in Ringaskiddy, Ireland, set to generate 500 …
Sanofi accuses MSD of US patent infringement
September 19, 2016Sales and Marketing MSD, Sanofi, lawsuit
Sanofi has filed a suit against MSD in the United States District Court for the District of Delaware accusing the …
Precision medicine reveals ‘Achilles heel’ in chronic myeloid leukaemia
September 16, 2016Medical Communications University of Glasgow, chronic myeloid leukaemia
Scientists at the University of Glasgow believe they have revealed an ‘Achilles heel’ of chronic myeloid leukaemia (CML), making their …
Top Ten articles in the Pharma Industry this week
September 16, 2016Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto
As we come to the end of another week, we’re looking back at an exciting week in the industry; there …
Teva and Intel team up to tackle Huntington’s with wearable tech
September 16, 2016Medical Communications Huntington's, Intel, Teva, wearable tech
Israeli pharma firm Teva is joining forces with technology giant Intel to tackle the debilitating disease Huntington’s with cutting-edge wearable …
Dechra signs £31 million acquisition
September 16, 2016Medical Communications Apex Laboratories, Dechra, acquisition
Dechra has agreed a deal to acquire veterinary pharmaceutical company Australian firm Apex Laboratories for AUS $55 (£31.3) million. The …
Novo Nordisk’s diabetes drug “significantly reduced’ cardiovascular risk
September 16, 2016Medical Communications Novo Nordisk, diabetes, semaglutide
Novo Nordisk has announced that its diabetes drug semaglutide “significantly reduced” the risk of major cardiovascular events at the 52nd …
Cirrus – a new name for specialist artwork services
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Multi Packaging Solutions (“MPS”), a global leader in value-added print and packaging solutions for the pharmaceutical, healthcare and FMCG sectors, …
New immunology and inflammation research global head and North American CSO for Sanofi
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, appointment
Sanofi has announced the appointment of Dr Frank Nestle as both the global head of immunology and inflammation research therapeutic …
Levi Garraway to succeed Richard Gaynor as senior VP of Global Oncology at Lilly
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, appointment
Eli Lilly has announced that Dr Levi Garraway will join the company as its senior vice president, Global Development & …
Allergan snaps up Vitae Pharma for $639 million
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Vitae, acquisition
Allergan has agreed to buy clinical-stage biotech Vitae Pharmaceuticals for $639 million, or $21 a share – more than double …
UK Biopharma and life after Brexit
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing brexit
Originally published in the September issue of Pharmafocus, Paul Ranson of global law firm Morgan Lewis’ London Life Sciences Practice …
Mylan CEO to appear before US congress over EpiPen scandal
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Hilary Clinton, Mylan, epipen
Following the controversy of Mylan’s price increases to its EpiPen (epinephrine) auto-injector, the company’s CEO Heather Bresch is due to …
GSK’s shingles vaccine tops MSD rival in Ph III testing
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
GlaxoSmithKline’s shingles vaccine Shingrix has topped rival MSD treatment Zostavax as it is shown to remain effective in elderly patients …
EU approval for Eisai kidney cancer treatment
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, Eisai, Kisplyx, Lenvima, everolimus
The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …
Bayer acquires Monsanto in largest-ever deal by a German company
September 14, 2016Business Services, Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto
Bayer and Monsanto have signed a definitive merger agreement under which the German drugmaker will acquire the US agricultural group …
Sanofi reveals promising data for FDA-delayed diabetes drug
September 14, 2016Research and Development, Sales and Marketing FDA, Lantus, Sanofi, iglarlixi
Sanofi has announced new Phase III data for its IGlarLixi combination drug for the treatment of diabetes, showing it could …
Latest content
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
